The global antibody discovery services and platforms market is expected to reach USD 1.6 billion by 2023 anticipated to grow at a CAGR of 12% during the forecast period 2023-2035.

Developing drugs, from discovery to market, usually spans 10-15 years and involves substantial investments, often exceeding $2 billion. Unfortunately, more than 90% of drug candidates don’t pass clinical trials. To streamline this process, reduce timelines, and manage the risk, pharmaceutical companies are outsourcing aspects of their discovery work to specialized contract research organizations (CROs). Collaborating with antibody CROs helps companies in the antibody discovery market optimize resources, cut costs, and tap into a global scientific talent pool, enhancing efficiency and success rates in bringing new antibody-based therapies to market.

Monoclonal antibody-based therapies, like Orthoclone OKT3? approved in 1986, have advanced significantly. They’ve diversified in formats, undergone engineering improvements, and benefited from innovative discovery methods. Over 160 monoclonal antibodies have been approved for various diseases, including cancer, chronic inflammatory conditions, infectious diseases, and cardiovascular ailments. Recently, therapies like ELREXFIO?, TALVEY?, Rystiggo?, COLUMVI?, and EPKINLY? were approved between May 2023 and August 2023. Due to the complexity of discovering these antibodies, many companies choose to license specialized antibody discovery platforms and technologies. The growing demand for antibody-based therapies and the preference for outsourcing indicate a significant expected expansion in antibody discovery services and platforms in the future.

Report Coverage
? The report extensively examines the antibody discovery market, categorizing it by service type, discovery method, antibody type, nature, therapeutic fields, and key geographical regions.
? It thoroughly analyzes market growth influencers such as drivers, restraints, opportunities, and challenges.
? The report evaluates both advantages and obstacles within the market landscape and offers insights into the competitive environment among top market players.
? Revenue forecasts for market segments are provided across six major regions.
? Detailed insights into the systematic research approach, methodologies, assumptions, and quality control measures employed ensure the accuracy and reliability of findings.
? Analysis encompasses historical trends, currency fluctuations, foreign exchange impacts, recession effects, and inflation measurements affecting antibody discovery services and platforms.
? It provides a concise overview of the present market status and forecasts the short, mid, and long-term evolution of the antibody discovery services and platforms market.
? Comprehensive coverage of historical context, structural details, isotypes, mechanisms of action, and applications of antibodies, with emphasis on monoclonal, bispecific, and polyclonal types.
? Detailed examination and comparison of discovery methods, tracking the developmental trends of monoclonal antibodies from murine to human variants over the past three decades.
? Analysis of over 160 active service providers based on various parameters such as establishment year, company size, location, services offered, discovery methods, animal models used, types of antibodies, and purposes.
? Comparative evaluation of companies based on experience, platforms, services offered, discovery methods, antibody formats, application areas, and regional capabilities.
? In-depth profiles of companies providing antibody discovery services, including company overview, recent developments, and future outlook.
? Examination of 290+ platforms based on antibody types, discovery methods, animal models, establishment year, company size, and headquarters location.
? Assessment of leading market players considering supplier power, platform specifications, antibody compatibility, and deals signed between 2015-2023.
? Detailed information about companies offering access/licenses to their antibody discovery platforms or technologies, including company overview, platform details, recent developments, and future outlook.
? Evaluation of partnerships established within the antibody discovery market from 2021-2023, with descriptions of partnership models adopted by stakeholders.
? Examination of investments in the antibody discovery market from 2016-2023 across various financing stages and sources.
? Insights into cash flows, net present values, and scenarios of upfront, milestone, and royalty payments between licensors and licensees.
? Detailed discussion on industry-specific trends, market drivers, challenges, key players, and influencing factors in antibody humanization services.
? Presentation of detailed profiles of top-selling drugs in 2022, including historical sales, discovery processes, and methods.
? Discussion on upcoming antibody therapeutics and technologies expected to impact the industry’s evolution in the coming decade.

Key Market Companies
? Ablexis
? Antibody Solutions
? ChemPartner
? Creative Biolabs
? GenScript
? Genmab
? Harbour BioMed
? ImmunoPrecise
? MabSilico
? Myrio Therapeutics
? Nona Biosciences
? Rockland Immunochemicals
? Synbio technologies
? WuXi Biologics